A vaccine against an explosively spreading virus

Comment

Antonio Cassone. Pathog Glob Health. 2015 Mar.

. 2015 Mar;109(2):43.

doi: 10.1179/2047772415Z.000000000253.

No abstract available

Comment on

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE; VRC 311 Study Team. Chang LJ, et al. Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14. Lancet. 2014. PMID: 25132507 Clinical Trial.

1. Johansson MA. Chikungunya on the move. Trends Parasitol. 2015;31(2)):43–5. - PMC - PubMed
1. Rezza G. Dengue and Chikungunya: long-distance spread and outbreaks in native areas. Path Global Health. 2014;108:349–55. - PMC - PubMed
1. Rezza G, Nicoletti L, Angelina R, Romi R, Finarelli AC, Panning M et al. Infection with Chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370:1840–6. - PubMed
1. Weaver FC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012;11:1087–101. - PMC - PubMed
1. Chang L, Dowd KA, Mendoza FH, Saunders JG, Siter A, Plummer SH et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014;384:2046–52. - PubMed